Shots:

• The company will initiate the P-I/II dose-escalation & expansion study to evaluate the safety, PK & anti-tumor activities of IMP9064 as monothx. & in combination with Senaparib in patients with advanced solid tumors
• In preclinical studies, IMP9064 was a highly potent ATR inhibitor & selective against other kinases & showed high activities in several ATM-deficient cell lines compared to reference compounds in xenograft in vivo models
• IMP9064 is an ATR inhibitor while Senaparib is a PARP inhibitor which has been evaluated in multiple clinical studies globally. The company has designed a clinical strategy for IMP9064 to advance clinical development & provides benefits to patients globally

to­Ref: PRNewswire | Image: Crunchbase